Gynecological tumor chemotherapy patient carry-on remote follow-up visit method and system based on AI large model

Abstract

The invention discloses a gynecological tumor chemotherapy patient carry-on remote follow-up visit method and system based on an AI large model, relates to the field of medical treatment, and solves the problem that an existing gynecological tumor chemotherapy patient carry-on remote follow-up visit method is poor in effect. The method comprises the following steps: S1, carrying out periodic heart rate index monitoring on a gynecological tumor chemotherapy patient in a carry-on index monitoring period, and obtaining a heart rate carry-on monitoring abnormal value according to a monitoring result, S2, carrying out periodic blood oxygen index monitoring on the gynecological tumor chemotherapy patient in the carry-on index monitoring period, and obtaining a blood oxygen carry-on monitoring abnormal value according to the monitoring result, s3, the gynecological tumor chemotherapy patients are divided into the first follow-up diagnosis type gynecological tumor chemotherapy patients and the second follow-up diagnosis type gynecological tumor chemotherapy patients, remote follow-up diagnosis early warning is carried out, the accuracy of follow-up visit results is effectively improved, and therefore guarantee is provided for the clinical treatment effect of the patients.

Description

Technical Field

[0001] The present invention belongs to the medical field and relates to the A1 large model technology. Specifically, it is a method and system for remote follow-up of gynecological oncology chemotherapy patients based on the AI large model. Background Art

[0002] When the existing method for remote follow-up of gynecological oncology chemotherapy patients conducts remote follow-up, it has the following specific defects:

[0003] 1. When the existing method for remote follow-up of gynecological oncology chemotherapy patients conducts remote follow-up, it relies on users to output physiological indicators and cannot achieve automated collection of physiological indicators, resulting in low data collection efficiency and lack of flexibility in the follow-up process.

[0004] 2. When the existing method for remote follow-up of gynecological oncology chemotherapy patients conducts remote follow-up, it can only obtain physiological indicator data based on sensing devices and cannot collect symptoms for specific types of patients and give follow-up warnings, thus easily leading to lack of accuracy in the follow-up effect.

[0005] Therefore, we propose a method and system for remote follow-up of gynecological oncology chemotherapy patients based on the AI large model. Summary of the Invention

[0006] Aiming at the deficiencies of the existing technology, the purpose of the present invention is to provide a method and system for remote follow-up of gynecological oncology chemotherapy patients based on the AI large model, aiming to improve the accuracy of follow-up results.

[0007] To achieve the above purpose, the present invention adopts the following technical solutions: A method for remote follow-up of gynecological oncology chemotherapy patients based on the AI large model includes the following specific steps:

[0008] Step S1: Obtain the portable index monitoring period, conduct periodic heart rate index monitoring on gynecological oncology chemotherapy patients in the portable index monitoring period, and obtain the abnormal values of heart rate portable monitoring according to the monitoring results.

[0009] Step S2: Conduct periodic blood oxygen index monitoring on gynecological oncology chemotherapy patients in the portable index monitoring period, and obtain the abnormal values of blood oxygen portable monitoring according to the monitoring results.

[0010] Step S3: Divide gynecological oncology chemotherapy patients into first follow-up type gynecological oncology chemotherapy patients and second follow-up type gynecological oncology chemotherapy patients according to the abnormal values of heart rate portable monitoring and blood oxygen portable monitoring, and give remote follow-up warnings respectively.

[0011] Furthermore, it is characterized in that in step S1, the following specific steps are further included:

[0012] Step S11: During the follow-up period of gynecological oncology chemotherapy patients, mark the time value corresponding to the current moment as the cycle end time point, and define a portable index monitoring cycle with a fixed time length;

[0013] Step S12: Mark several heart rate monitoring time points within the portable index monitoring cycle, and name the marked several heart rate monitoring time points in chronological order as the X1 heart rate monitoring time point to the Xa heart rate monitoring time point;

[0014] Step S13: Obtain the patient's heart rate values corresponding to the X1 heart rate monitoring time point to the Xa heart rate monitoring time point of the gynecological oncology chemotherapy patient through the smart wearable device, and obtain the patient's X1 heart rate value to the Xa heart rate value;

[0015] Step S14: Obtain the normal heart rate range corresponding to the gynecological oncology chemotherapy patient through big data, and obtain the median of the normal heart rate range to obtain the patient's heart rate reference value;

[0016] Step S15: Obtain the ratio of the number of abnormal heart rates in the cycle;

[0017] Step S16: Obtain the patient's cycle heart rate deviation;

[0018] Step S17: Calculate the average of the patient's X1 heart rate value to the Xa heart rate value to obtain the patient's cycle heart rate average value, calculate the difference between the patient's cycle heart rate average value and the patient's heart rate reference value, and take the absolute value of the obtained difference to obtain the patient's cycle heart rate deviation;

[0019] Step S18: Obtain the abnormal value of heart rate portable monitoring by calculating the average deviation of abnormal heart rates in the cycle, the patient's cycle heart rate deviation, and the ratio of the number of abnormal heart rates in the cycle;

[0020] Calculate the abnormal value of heart rate portable monitoring.

[0021] Furthermore, in the step S15, the following specific steps are further included:

[0022] Step S151: Determine the existence of the patient's X1 heart rate value to the Xa heart rate value and the normal heart rate range. When the patient's Xi heart rate value is within the normal heart rate range, mark the patient's Xi heart rate value as a normal heart rate value. When the patient's Xi heart rate value is not within the normal heart rate range, mark the patient's Xi heart rate value as an abnormal heart rate value;

[0023] Step S152: Count the number of abnormal heart rate values among the patient's X1 heart rate value to the Xa heart rate value to obtain the number value of abnormal heart rates, and calculate the ratio of the abnormal heart rate value to a to obtain the ratio of the number of abnormal heart rates in the cycle.

[0024] Furthermore, in step S16, the following specific steps are further included:

[0025] Step S161: Obtain the left boundary of the normal heart rate interval to get the first interval boundary value, and obtain the right boundary value of the normal heart rate interval to get the second interval boundary value;

[0026] Step S162: When the heart rate value of patient Xj is greater than the second interval boundary value, calculate the difference between the heart rate value of patient Xj and the second interval boundary, and take the absolute value of the obtained difference to get the heart rate abnormal deviation corresponding to the heart rate monitoring time point of Xj;

[0027] Step S163: When the heart rate value of patient Xj is less than the first interval boundary value, calculate the difference between the heart rate value of patient Xj and the first interval boundary, and take the absolute value of the obtained difference to get the heart rate abnormal deviation corresponding to the heart rate monitoring time point of Xj;

[0028] Step S164: Respectively obtain the heart rate abnormal deviations corresponding to each abnormal heart rate value to get multiple heart rate abnormal deviations, and calculate the average of the obtained multiple heart rate abnormal deviations to get the average abnormal heart rate deviation of the cycle.

[0029] Furthermore, in step S2, the following specific steps are further included:

[0030] Step S21: Mark several blood oxygen monitoring time points within the portable index monitoring cycle, and name the marked several blood oxygen monitoring time points as the blood oxygen monitoring time point of Y1 to the blood oxygen monitoring time point of Yb in chronological order;

[0031] Step S22: Respectively obtain the blood oxygen values of the gynecological tumor chemotherapy patients corresponding to the blood oxygen monitoring time point of Y1 to the blood oxygen monitoring time point of Yb through the smart wearable device to get the blood oxygen values of patient Y1 to Yb;

[0032] Step S23: Obtain the normal blood oxygen interval corresponding to the gynecological tumor chemotherapy patients through big data, and obtain the interval median of the normal blood oxygen interval to get the patient's blood oxygen reference value;

[0033] Step S24: Obtain the ratio of the number of abnormal blood oxygen in the cycle;

[0034] Step S25: Obtain the average deviation of abnormal blood oxygen in the cycle;

[0035] Step S26: Calculate the average of the blood oxygen values of patient Y1 to Yb to get the average blood oxygen value of the patient in the cycle, calculate the difference between the average blood oxygen value of the patient in the cycle and the patient's blood oxygen reference value, and take the absolute value of the obtained difference to get the blood oxygen deviation of the patient in the cycle;

[0036] Step S27: Calculate the abnormal value of ambulatory blood oxygen monitoring by using the average deviation of abnormal periodic blood oxygen, the blood oxygen deviation of the patient's cycle, and the ratio of the number of abnormal periodic blood oxygen.

[0037] Calculate the abnormal value of ambulatory blood oxygen monitoring.

[0038] Furthermore, in step S24, the following specific steps are further included:

[0039] Step S241: Determine the existence of the blood oxygen values from the blood oxygen value of patient Y1 to the blood oxygen value of Yb in the normal blood oxygen range. When the blood oxygen value of patient Ym is within the normal blood oxygen range, mark the blood oxygen value of patient Ym as a normal blood oxygen value. When the blood oxygen value of patient Ym is not within the normal blood oxygen range, mark the blood oxygen value of patient Ym as an abnormal blood oxygen value.

[0040] Step S242: Count the number of abnormal blood oxygen values among the blood oxygen values from the blood oxygen value of patient Y1 to the blood oxygen value of Yb to obtain the number value of abnormal blood oxygen. Calculate the ratio of the abnormal blood oxygen value to b to obtain the ratio of the number of abnormal periodic blood oxygen.

[0041] Furthermore, in step S25, the following specific steps are further included:

[0042] Step S251: Obtain the left boundary of the normal blood oxygen range to get the first blood oxygen range boundary value, and obtain the right boundary value of the normal blood oxygen range to get the second blood oxygen range boundary value.

[0043] Step S252: If the blood oxygen value of patient Yn is greater than the second blood oxygen range boundary value, calculate the difference between the blood oxygen value of patient Yn and the second blood oxygen range boundary value, and take the absolute value of the obtained difference to get the blood oxygen abnormal deviation corresponding to the blood oxygen monitoring time point of Yn.

[0044] Step S253: If the blood oxygen value of patient Yn is less than the first blood oxygen range boundary value, calculate the difference between the blood oxygen value of patient Yn and the first blood oxygen range boundary value, and take the absolute value of the obtained difference to get the blood oxygen abnormal deviation corresponding to the blood oxygen monitoring time point of Yn.

[0045] Step S254: Respectively obtain the blood oxygen abnormal deviations corresponding to each abnormal blood oxygen value to get multiple blood oxygen abnormal deviations, and calculate the average of the obtained multiple blood oxygen abnormal deviations to get the average deviation of abnormal periodic blood oxygen.

[0046] Furthermore, in step S3, the following specific steps are further included:

[0047] Step S31: Respectively obtain the abnormal value of ambulatory heart rate monitoring and the abnormal value of ambulatory blood oxygen monitoring.

[0048] Step S32: Calculate the coefficient of physiological index wearable monitoring from the abnormal values of heart rate wearable monitoring and the abnormal values of blood oxygen wearable monitoring;

[0049] Calculate the coefficient of physiological index wearable monitoring. The specific formula is as follows:

[0050] Slx = Xyy × a1 + Xly

[0051] Where Slx is the coefficient of physiological index wearable monitoring, Xyy is the abnormal value of blood oxygen wearable monitoring, a1 is the set proportional coefficient, and Xly is the abnormal value of heart rate wearable monitoring

[0052] Step S33: Obtain the interval of the physiological index monitoring coefficient. If the coefficient of physiological index wearable monitoring is within the interval of the physiological index monitoring coefficient, determine that the corresponding gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient; if the coefficient of physiological index wearable monitoring is not within the interval of the physiological index monitoring coefficient, determine that the corresponding gynecological oncology chemotherapy patient is a second follow-up type gynecological oncology chemotherapy patient;

[0053] Step S34: Conduct remote follow-up warnings for the first follow-up type gynecological oncology chemotherapy patients and the second follow-up type gynecological patients respectively.

[0054] Furthermore, in the said Step S34, the following specific steps are further included:

[0055] Step S341: When the gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient, the gynecological oncology chemotherapy patient can choose to conduct a current symptom Q&A with the A1 model built in the smart wearable device. The A1 model extracts the text of the current symptoms spoken by the gynecological oncology chemotherapy patient to obtain the patient symptom data, and compares the patient symptom data with the built-in alarm symptoms in text. If there are alarm symptoms in the patient symptom data, the smart wearable device issues a remote warning; if there are no alarm symptoms in the patient symptom data, the smart wearable device does not issue a remote warning;

[0056] Step S342: When the gynecological oncology chemotherapy patient is a second follow-up type gynecological oncology chemotherapy patient, the smart wearable device issues a remote warning.

[0057] A remote follow-up system for gynecological oncology chemotherapy patients based on the AI large model includes:

[0058] Heart rate index module: used to obtain the wearable index monitoring period, conduct periodic heart rate index monitoring on gynecological oncology chemotherapy patients during the wearable index monitoring period, and obtain the abnormal values of heart rate wearable monitoring according to the monitoring results;

[0059] Blood oxygen index module: It is used to periodically monitor the blood oxygen index of gynecological oncology chemotherapy patients during the personal index monitoring period, and obtain abnormal values of blood oxygen personal monitoring according to the monitoring results;

[0060] Follow-up warning module: Classify gynecological oncology chemotherapy patients into first follow-up type gynecological oncology chemotherapy patients and second follow-up type gynecological oncology chemotherapy patients according to abnormal values of heart rate personal monitoring and abnormal values of blood oxygen personal monitoring, and conduct remote follow-up warnings respectively.

[0061] In summary, due to the adoption of the above technical solutions, the beneficial effects of the present invention are as follows:

[0062] 1. The present invention analyzes physiological indicators by automatically collecting abnormal values of heart rate personal monitoring and abnormal values of blood oxygen personal monitoring, which can effectively improve the data collection efficiency and enhance the accuracy and reliability of the data.

[0063] 2. The present invention collects and analyzes symptoms for specific types of patients, and conducts follow-up warnings according to the analysis results, which can effectively improve the accuracy of follow-up results and ensure the clinical treatment effect of patients.

[0064] Brief description of the drawings (not seen Figure 1 , Figure 2 )

[0065] For the convenience of those skilled in the art to understand, the present invention will be further described below in conjunction with the drawings.

[0066] Figure 1 is the implementation step diagram of the present invention;

[0067] Figure 2 is the overall system block diagram of the present invention. Detailed implementation manners

[0068] The technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0069] Embodiment 1

[0070] Please refer to Figure 1 , the present invention provides a technical solution: A method for remote follow-up of gynecological oncology chemotherapy patients based on an AI large model, including the following specific steps:

[0071] Step S1: Create a portable indicator monitoring period, conduct periodic heart rate indicator monitoring on gynecological oncology chemotherapy patients within the portable indicator monitoring period, and obtain abnormal heart rate values for portable monitoring based on the monitoring results;

[0072] In step S1, the following specific steps are further included:

[0073] Step S11: During the follow-up period of gynecological oncology chemotherapy patients, mark the time value corresponding to the current moment as the cycle end time point and define a portable indicator monitoring period with a fixed time length;

[0074] Step S12: Mark several heart rate monitoring time points within the portable indicator monitoring period, and name the marked several heart rate monitoring time points as the X1 heart rate monitoring time point to the Xa heart rate monitoring time point in chronological order;

[0075] Step S13: Use a smart wearable device to obtain the patient's heart rate values corresponding to the X1 heart rate monitoring time point to the Xa heart rate monitoring time point of the gynecological oncology chemotherapy patient respectively, and obtain the patient's X1 heart rate value to Xa heart rate value;

[0076] Step S14: Obtain the normal heart rate range corresponding to the gynecological oncology chemotherapy patient through big data, and obtain the median of the normal heart rate range to get the patient's heart rate reference value;

[0077] Step S15: Obtain the ratio of the number of abnormal heart rates in the cycle;

[0078] In step S15, the following specific steps are further included:

[0079] Step S151: Determine the existence of the patient's X1 heart rate value to Xa heart rate value in the normal heart rate range. When the patient's Xi heart rate value is within the normal heart rate range, mark the patient's Xi heart rate value as a normal heart rate value. When the patient's Xi heart rate value is not within the normal heart rate range, mark the patient's Xi heart rate value as an abnormal heart rate value;

[0080] Step S152: Count the number of abnormal heart rate values among the patient's X1 heart rate value to Xa heart rate value to obtain the number of abnormal heart rates, and calculate the ratio of the abnormal heart rate value to a to obtain the ratio of the number of abnormal heart rates in the cycle;

[0081] Step S16: Obtain the patient's cycle heart rate deviation;

[0082] In step S16, the following specific steps are further included:

[0083] Step S161: Obtain the left boundary of the normal heart rate range to get the first range boundary value, and obtain the right boundary value of the normal heart rate range to get the second range boundary value;

[0084] Step S162: If the heart rate value of patient Xj is greater than the second range boundary value, calculate the difference between the heart rate value of patient Xj and the second range boundary, and take the absolute value of the obtained difference to get the heart rate abnormality deviation corresponding to the heart rate monitoring time point of Xj;

[0085] Step S163: If the heart rate value of patient Xj is less than the first range boundary value, calculate the difference between the heart rate value of patient Xj and the first range boundary, and take the absolute value of the obtained difference to get the heart rate abnormality deviation corresponding to the heart rate monitoring time point of Xj;

[0086] Step S164: Respectively obtain the heart rate abnormality deviations corresponding to each abnormal heart rate value to get multiple heart rate abnormality deviations, and calculate the average of the obtained multiple heart rate abnormality deviations to get the average deviation of periodic abnormal heart rate;

[0087] Step S17: Calculate the average of the heart rate values of patient X1 to Xa to get the average periodic heart rate of the patient, calculate the difference between the average periodic heart rate of the patient and the heart rate reference value of the patient, and take the absolute value of the obtained difference to get the periodic heart rate deviation of the patient;

[0088] Step S18: Calculate the heart rate portable monitoring abnormality value through the average deviation of periodic abnormal heart rate, the periodic heart rate deviation of the patient, and the ratio of the number of periodic abnormal heart rates;

[0089] Calculate the heart rate portable monitoring abnormality value, and the specific formula is as follows:

[0090] Xly = Ycp × Xsb + Xpp;

[0091] Where, Xly is the heart rate portable monitoring abnormality value, Ycp is the average deviation of periodic abnormal heart rate, Xsb is the ratio of the number of periodic abnormal heart rates, and Xpp is the periodic heart rate deviation of the patient;

[0092] Step S2: Conduct periodic blood oxygen index monitoring on gynecological oncology chemotherapy patients in the portable index monitoring period, and obtain the blood oxygen portable monitoring abnormality value according to the monitoring results;

[0093] In the said step S2, it further includes the following specific steps:

[0094] Step S21: Mark several blood oxygen monitoring time points within the portable index monitoring period, and name the marked several blood oxygen monitoring time points as the Y1 blood oxygen monitoring time point to the Yb blood oxygen monitoring time point in sequence according to the time sequence;

[0095] Step S22: Obtain the patient's blood oxygen values corresponding to the gynecological oncology chemotherapy patients at the Y1 blood oxygen monitoring time point to the Yb blood oxygen monitoring time point through the smart wearable device, and obtain the patient's Y1 blood oxygen value to Yb blood oxygen value;

[0096] Step S23: Obtain the normal blood oxygen range corresponding to the gynecological oncology chemotherapy patients through big data, and obtain the median of the normal blood oxygen range to obtain the patient's blood oxygen reference value;

[0097] Step S24: Obtain the ratio of the number of abnormal blood oxygen in the cycle;

[0098] In the above-mentioned step S24, the following specific steps are further included:

[0099] Step S241: Determine the existence of the patient's Y1 blood oxygen value to Yb blood oxygen value and the normal blood oxygen range. When the patient's Ym blood oxygen value is within the normal blood oxygen range, mark the patient's Ym blood oxygen value as a normal blood oxygen value. When the patient's Ym blood oxygen value is not within the normal blood oxygen range, mark the patient's Ym blood oxygen value as an abnormal blood oxygen value;

[0100] Step S242: Count the number of abnormal blood oxygen values among the patient's Y1 blood oxygen value to Yb blood oxygen value to obtain the abnormal blood oxygen quantity value, and calculate the ratio of the abnormal blood oxygen value to b to obtain the ratio of the number of abnormal blood oxygen in the cycle;

[0101] Step S25: Obtain the average deviation of abnormal blood oxygen in the cycle;

[0102] In the above-mentioned step S25, the following specific steps are further included:

[0103] Step S251: Obtain the left boundary of the normal blood oxygen range to obtain the first blood oxygen range boundary value, and obtain the right boundary value of the normal blood oxygen range to obtain the second blood oxygen range boundary value;

[0104] Step S252: If the patient's Yn blood oxygen value is greater than the second blood oxygen range boundary value, calculate the difference between the patient's Yn blood oxygen value and the second blood oxygen range boundary value, and take the absolute value of the obtained difference to obtain the blood oxygen abnormal deviation corresponding to the Yn blood oxygen monitoring time point;

[0105] Step S253: If the patient's Yn blood oxygen value is less than the first blood oxygen range boundary value, calculate the difference between the patient's Yn blood oxygen value and the first blood oxygen range boundary value, and take the absolute value of the obtained difference to obtain the blood oxygen abnormal deviation corresponding to the Yn blood oxygen monitoring time point;

[0106] Step S254: Obtain the blood oxygen abnormal deviation corresponding to each abnormal blood oxygen value respectively, get a plurality of blood oxygen abnormal deviations, and calculate the average value of the obtained plurality of blood oxygen abnormal deviations to obtain the average abnormal blood oxygen deviation of the cycle;

[0107] Step S26: Calculate the average value of the blood oxygen values from the blood oxygen value of patient Y1 to the blood oxygen value of Yb to obtain the average blood oxygen value of the patient's cycle, calculate the difference between the average blood oxygen value of the patient's cycle and the blood oxygen reference value of the patient, and take the absolute value of the obtained difference to obtain the blood oxygen deviation of the patient's cycle;

[0108] Step S27: Obtain the abnormal value of blood oxygen portable monitoring by calculating the average abnormal blood oxygen deviation of the cycle, the blood oxygen deviation of the patient's cycle, and the ratio of the number of abnormal blood oxygen in the cycle;

[0109] Calculate the abnormal value of blood oxygen portable monitoring, and the specific formula is as follows:

[0110] Xyy = Yyp × Xyb + Xyp;

[0111] Wherein, Xyy is the abnormal value of blood oxygen portable monitoring, Yyp is the average abnormal blood oxygen deviation of the cycle, Xyb is the ratio of the number of abnormal blood oxygen in the cycle, and Xyp is the blood oxygen deviation of the patient's cycle;

[0112] Step S3: Divide the gynecological tumor chemotherapy patients into the first follow-up type gynecological tumor chemotherapy patients and the second follow-up type gynecological tumor chemotherapy patients according to the abnormal value of blood oxygen portable monitoring and the abnormal value of heart rate portable monitoring, and conduct remote follow-up warnings respectively;

[0113] In the said step S3, it further includes the following specific steps:

[0114] Step S31: Obtain the abnormal value of heart rate portable monitoring and the abnormal value of blood oxygen portable monitoring respectively;

[0115] Step S32: Obtain the physiological index portable monitoring coefficient by calculating the abnormal value of heart rate portable monitoring and the abnormal value of blood oxygen portable monitoring;

[0116] Calculate the physiological index portable monitoring coefficient, and the specific formula is as follows:

[0117] Slx = Xyy × a1 + Xly

[0118] Wherein, Slx is the physiological index portable monitoring coefficient, Xyy is the abnormal value of blood oxygen portable monitoring, a1 is the set proportional coefficient, and Xly is the abnormal value of heart rate portable monitoring;

[0119] Step S33: Obtain the physiological index monitoring coefficient range. If the physiological index portable monitoring coefficient is within the physiological index monitoring coefficient range, it is determined that the corresponding gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient. If the physiological index portable monitoring coefficient is not within the physiological index monitoring coefficient range, it is determined that the corresponding gynecological oncology chemotherapy patient is a second follow-up type gynecological oncology chemotherapy patient;

[0120] Step S34: Conduct remote follow-up warnings for the first follow-up type gynecological oncology chemotherapy patients and the second follow-up type gynecological patients respectively;

[0121] In the said step S34, the following specific steps are further included:

[0122] Step S341: When the gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient, the gynecological oncology chemotherapy patient can choose to conduct a current symptom Q&A with the A1 model built into the smart wearable device. The A1 model extracts the text of the current symptoms output by the gynecological oncology chemotherapy patient through voice to obtain patient symptom data, and compares the patient symptom data with the built-in alarm symptoms in text. If there are alarm symptoms in the patient symptom data, the smart wearable device issues a remote warning. If there are no alarm symptoms in the patient symptom data, the smart wearable device does not issue a remote warning;

[0123] Step S342: When the gynecological oncology chemotherapy patient is a second follow-up type gynecological oncology chemotherapy patient, the smart wearable device issues a remote warning;

[0124] In this application, if there are corresponding calculation formulas, the above calculation formulas are all dimensionless and take their numerical values for calculation. For the coefficients such as weight coefficients and proportionality coefficients existing in the formulas, the magnitudes set are for obtaining a result value by quantifying each parameter. Regarding the magnitudes of the weight coefficients and proportionality coefficients, as long as the proportional relationship between the parameters and the result value is not affected.

[0125] Embodiment 2

[0126] Please refer to Figure 2 , based on another concept of the same invention, a portable remote follow-up system for gynecological oncology chemotherapy patients based on the AI large model is proposed, including a heart rate index module, a blood oxygen index module, a follow-up warning module, and a server. The heart rate index module, the blood oxygen index module, and the follow-up warning module are respectively connected to the server, and the server controls the heart rate index module, the blood oxygen index module, and the follow-up warning module respectively;

[0127] Create a portable index monitoring period, conduct periodic heart rate index monitoring on gynecological oncology chemotherapy patients in the portable index monitoring period, and obtain the abnormal heart rate portable monitoring values according to the monitoring results;

[0128] During the follow-up period of gynecological oncology chemotherapy patients, mark the time value corresponding to the current moment as the cycle end time point, and define a portable index monitoring cycle with a fixed time length;

[0129] It should be noted here that:

[0130] In this application, since the time value corresponding to the current moment changes dynamically, the start time point of the portable index monitoring cycle also changes dynamically, thus realizing the dynamic update of the portable index monitoring cycle;

[0131] In specific implementation, the time length of the portable index monitoring cycle is specifically the average value of the patient's historical measurement cycles. In specific implementation, if the cumulative duration of the intelligent wearable device measuring the patient's heart rate and blood oxygen for the A-th time is 80s, the cumulative duration for the B-th time is 83s, and the cumulative duration for the C-th time is 78s, then the portable index monitoring cycle can be calculated to be 80.3.

[0132] The heart rate index module periodically monitors the heart rate index of gynecological oncology chemotherapy patients in the portable index monitoring cycle, and obtains the abnormal values of the portable heart rate monitoring according to the monitoring results;

[0133] Specifically as follows:

[0134] Mark several heart rate monitoring time points within the portable index monitoring cycle, and name the several marked heart rate monitoring time points in chronological order as the X1 heart rate monitoring time point to the Xa heart rate monitoring time point;

[0135] It should be noted here that:

[0136] In this application, X involved here is the identifier corresponding to the heart rate monitoring time point, and a is the numerical value corresponding to the number of heart rate monitoring time points, and a is an integer greater than 1.

[0137] Obtain the patient's heart rate values corresponding to the X1 heart rate monitoring time point to the Xa heart rate monitoring time point of the gynecological oncology chemotherapy patient through the intelligent wearable device respectively, and obtain the patient's X1 heart rate value to the Xa heart rate value;

[0138] Obtain the normal heart rate range corresponding to the gynecological oncology chemotherapy patient through big data, and obtain the median of the normal heart rate range to obtain the patient's heart rate reference value;

[0139] It should be noted here that:

[0140] In this application, the normal heart rate range involved here is the normal heart rate data of gynecological oncology chemotherapy patients in a non-exercising state. Through big data collection, the specific normal heart rate range is [60, 100], and the heart rate baseline value of the patient is calculated to be 80;

[0141] Determine the existence of the heart rate values of patient X1 to Xa compared with the normal heart rate range. When the heart rate value of patient Xi is within the normal heart rate range, mark the heart rate value of patient Xi as a normal heart rate value. When the heart rate value of patient Xi is not within the normal heart rate range, mark the heart rate value of patient Xi as an abnormal heart rate value;

[0142] It should be noted here that:

[0143] In this application, the heart rate value of patient Xi involved here can be any heart rate value from the heart rate values of patient X1 to Xa.

[0144] The normal heart rate values involved here include the interval boundaries of the normal heart rate range.

[0145] Count the number of abnormal heart rate values among the heart rate values of patient X1 to Xa to obtain the abnormal heart rate quantity value, and calculate the ratio of the abnormal heart rate value to a to obtain the periodic abnormal heart rate quantity ratio;

[0146] Obtain the left interval boundary value of the normal heart rate range to get the first interval boundary value, and obtain the right interval boundary value of the normal heart rate range to get the second interval boundary value;

[0147] It should be noted here that:

[0148] In this application, assuming the normal heart rate range is specifically [60, 100], then the first interval boundary value is 60, and the second interval boundary value is 100;

[0149] When the heart rate value of patient Xj is greater than the second interval boundary value, calculate the difference between the heart rate value of patient Xj and the second interval boundary, and take the absolute value of the obtained difference to get the heart rate abnormal deviation corresponding to the heart rate monitoring time point of Xj;

[0150] When the heart rate value of patient Xj is less than the first interval boundary value, calculate the difference between the heart rate value of patient Xj and the first interval boundary, and take the absolute value of the obtained difference to get the heart rate abnormal deviation corresponding to the heart rate monitoring time point of Xj;

[0151] It should be noted here that:

[0152] In this application, the heart rate value of patient Xj involved here is an abnormal heart rate value, and the heart rate monitoring time point of Xj is the heart rate monitoring time point corresponding to the abnormal heart rate value.

[0153] Obtain the heart rate abnormality deviation corresponding to each abnormal heart rate value respectively, obtain multiple heart rate abnormality deviations, and calculate the average of the obtained multiple heart rate abnormality deviations to obtain the average deviation of periodic abnormal heart rate;

[0154] Calculate the average of the heart rate values from the heart rate value of patient X1 to the heart rate value of Xa to obtain the average periodic heart rate of the patient, calculate the difference between the average periodic heart rate of the patient and the reference heart rate value of the patient, and take the absolute value of the obtained difference to obtain the periodic heart rate deviation of the patient;

[0155] Calculate the abnormal value of heart rate portable monitoring by using the average deviation of periodic abnormal heart rate, the periodic heart rate deviation of the patient, and the ratio of the number of periodic abnormal heart rates;

[0156] Calculate the abnormal value of heart rate portable monitoring, and the specific formula is as follows:

[0157] Xly = Ycp × Xsb + Xpp;

[0158] Wherein, Xly is the abnormal value of heart rate portable monitoring, Ycp is the average deviation of periodic abnormal heart rate, Xsb is the ratio of the number of periodic abnormal heart rates, and Xpp is the periodic heart rate deviation of the patient;

[0159] It should be noted here that:

[0160] In this application, the abnormal value of heart rate portable monitoring is an index value for measuring the abnormal heart rate state of gynecological oncology chemotherapy patients, and the abnormal value of heart rate portable monitoring is directly proportional to the average deviation of periodic abnormal heart rate, the periodic heart rate deviation of the patient, and the ratio of the number of periodic abnormal heart rates respectively;

[0161] In practical applications, during the process of monitoring the abnormal value of heart rate portable monitoring, there is an average deviation of periodic abnormal heart rate of 31, a ratio of the number of periodic abnormal heart rates of 0.2, and a periodic heart rate deviation of the patient of 15, and the calculated abnormal value of heart rate portable monitoring is 21.2.

[0162] Perform periodic blood oxygen index monitoring on gynecological oncology chemotherapy patients in the portable index monitoring period, and obtain the abnormal value of blood oxygen portable monitoring according to the monitoring results;

[0163] Specifically as follows:

[0164] Mark several blood oxygen monitoring time points within the portable index monitoring period, and name the marked several blood oxygen monitoring time points as the Y1 blood oxygen monitoring time point to the Yb blood oxygen monitoring time point in sequence according to the time sequence;

[0165] It should be noted here that:

[0166] In this application, Y involved here is an identifier corresponding to the blood oxygen monitoring time point, b is a numerical value corresponding to the blood oxygen monitoring time point, and b is an integer greater than 1.

[0167] The intelligent wearable device is used to obtain the patient's blood oxygen values corresponding to the blood oxygen monitoring time points from Y1 to Yb for the gynecological oncology chemotherapy patients respectively, so as to obtain the patient's blood oxygen values from Y1 to Yb.

[0168] The normal blood oxygen range corresponding to the gynecological oncology chemotherapy patients is obtained through big data, and the median of the normal blood oxygen range is obtained to get the patient's blood oxygen reference value.

[0169] It should be noted here that:

[0170] In this application, the normal blood oxygen range involved here is the normal blood oxygen data of the gynecological oncology chemotherapy patients in a non-moving state. The specific normal blood oxygen range obtained through big data collection is [95%, 100%], and the patient's blood oxygen reference value is calculated to be 97.5% accordingly.

[0171] The existence of the patient's blood oxygen values from Y1 to Yb is judged against the normal blood oxygen range. When the patient's blood oxygen value at Ym is within the normal blood oxygen range, the patient's blood oxygen value at Ym is marked as a normal blood oxygen value; when the patient's blood oxygen value at Ym is not within the normal blood oxygen range, the patient's blood oxygen value at Ym is marked as an abnormal blood oxygen value.

[0172] It should be noted here that:

[0173] In this application, the patient's blood oxygen value at Ym involved here can be any one of the patient's blood oxygen values from Y1 to Yb.

[0174] The normal blood oxygen values involved here include the blood oxygen range boundary values of the normal blood oxygen range.

[0175] The number of abnormal blood oxygen values among the patient's blood oxygen values from Y1 to Yb is counted to obtain the abnormal blood oxygen quantity value, and the ratio of the abnormal blood oxygen value to b is calculated to obtain the periodic abnormal blood oxygen quantity ratio.

[0176] The left boundary of the normal blood oxygen range is obtained to get the first blood oxygen range boundary value, and the right boundary value of the normal blood oxygen range is obtained to get the second blood oxygen range boundary value.

[0177] It should be noted here that:

[0178] In this application, assuming the normal blood oxygen range is specifically [95%, 100%], then the first blood oxygen range boundary value is 95%, and the second blood oxygen range boundary value is 100%.

[0179] When the blood oxygen value of patient Yn is greater than the boundary value of the second blood oxygen range, calculate the difference between the blood oxygen value of patient Yn and the boundary value of the second blood oxygen range, and take the absolute value of the obtained difference to obtain the blood oxygen abnormality deviation corresponding to the blood oxygen monitoring time point of Yn;

[0180] When the blood oxygen value of patient Yn is less than the boundary value of the first blood oxygen range, calculate the difference between the blood oxygen value of patient Yn and the boundary value of the first blood oxygen range, and take the absolute value of the obtained difference to obtain the blood oxygen abnormality deviation corresponding to the blood oxygen monitoring time point of Yn;

[0181] It should be noted here that:

[0182] In this application, the blood oxygen value of patient Yn involved here is an abnormal blood oxygen value, and the blood oxygen monitoring time point of Yn is the blood oxygen monitoring time point corresponding to the abnormal blood oxygen value.

[0183] Respectively obtain the blood oxygen abnormality deviation corresponding to each abnormal blood oxygen value, obtain a plurality of blood oxygen abnormality deviations, and calculate the average value of the obtained plurality of blood oxygen abnormality deviations to obtain the average abnormal blood oxygen deviation of the cycle;

[0184] Calculate the average value of the blood oxygen values of patient Y1 to Yb to obtain the average blood oxygen value of the patient's cycle, calculate the difference between the average blood oxygen value of the patient's cycle and the patient's blood oxygen reference value, and take the absolute value of the obtained difference to obtain the patient's cycle blood oxygen deviation;

[0185] Obtain the abnormal value of blood oxygen portable monitoring by calculating the average abnormal blood oxygen deviation of the cycle, the patient's cycle blood oxygen deviation, and the ratio of the number of abnormal blood oxygen in the cycle;

[0186] Calculate the abnormal value of blood oxygen portable monitoring, and the specific formula is as follows:

[0187] Xyy = Yyp × Xyb + Xyp;

[0188] Wherein, Xyy is the abnormal value of blood oxygen portable monitoring, Yyp is the average abnormal blood oxygen deviation of the cycle, Xyb is the ratio of the number of abnormal blood oxygen in the cycle, and Xyp is the patient's cycle blood oxygen deviation;

[0189] It should be noted here that:

[0190] In this application, the abnormal value of blood oxygen portable monitoring is an index value for measuring the abnormal state of blood oxygen in patients with gynecological tumor chemotherapy, and the abnormal value of blood oxygen portable monitoring is directly proportional to the average abnormal blood oxygen deviation of the cycle, the patient's cycle blood oxygen deviation, and the ratio of the number of abnormal blood oxygen in the cycle respectively;

[0191] In practical applications, during the process of monitoring the abnormal value of blood oxygen portable monitoring, there are the following test data:

[0192] The average deviation of abnormal blood oxygen in a cycle is 11%, the ratio of the number of abnormal blood oxygen in a cycle is 0.3, and the deviation of the patient's blood oxygen in a cycle is 21%. The abnormal value of portable blood oxygen monitoring is calculated to be 0.243.

[0193] The follow-up warning module conducts dynamic voice monitoring on gynecological oncology chemotherapy patients in the portable index monitoring cycle, and obtains the abnormal index value of cycle voice monitoring according to the monitoring results;

[0194] Specifically as follows:

[0195] Obtain the abnormal value of portable heart rate monitoring and the abnormal value of portable blood oxygen monitoring respectively;

[0196] Calculate the physiological index portable monitoring coefficient from the abnormal value of portable heart rate monitoring and the abnormal value of portable blood oxygen monitoring;

[0197] Calculate the physiological index portable monitoring coefficient, and the specific formula is as follows:

[0198] Slx = Xyy × a1 + Xly

[0199] Among them, Slx is the physiological index portable monitoring coefficient, Xyy is the abnormal value of portable blood oxygen monitoring, a1 is the set proportionality coefficient, and Xly is the abnormal value of portable heart rate monitoring;

[0200] It should be noted here that:

[0201] In this application, the specific function of the proportionality coefficient a1 involved here is to avoid the large difference in specific values caused by the numerical units between the abnormal value of portable heart rate monitoring and the abnormal value of portable blood oxygen monitoring. In this application, the specific value corresponding to a1 is 100;

[0202] Obtain the physiological index monitoring coefficient interval. If the physiological index portable monitoring coefficient is within the physiological index monitoring coefficient interval, it is determined that the corresponding gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient. If the physiological index portable monitoring coefficient is not within the physiological index monitoring coefficient interval, it is determined that the corresponding gynecological oncology chemotherapy patient is a second follow-up type gynecological oncology chemotherapy patient;

[0203] It should be noted here that:

[0204] In this application, the physiological index monitoring coefficient interval needs to be set with actual parameters according to the actual situation;

[0205] In specific implementation, there are the following test data:

[0206] The abnormal value of the blood oxygen portable monitor is 0.243, the set proportionality coefficient is 100, the abnormal value of the patient's heart rate portable monitor is 21.2, and the calculated coefficient of the physiological index portable monitor is 45.5; if the coefficient range of the physiological index monitor is [0, 60], then the corresponding gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient;

[0207] Remote follow-up warnings are respectively given to the first follow-up type gynecological oncology chemotherapy patients and the second follow-up type gynecological patients;

[0208] When the gynecological oncology chemotherapy patient is a first follow-up type gynecological oncology chemotherapy patient, the gynecological oncology chemotherapy patient can choose to have a current symptom Q&A with the A1 model built in the smart wearable device. The A1 model extracts the text of the current symptoms output by voice by the gynecological oncology chemotherapy patient to obtain the patient symptom data, and compares the patient symptom data with the built-in alarm symptoms in text. If there are alarm symptoms in the patient symptom data, the smart wearable device issues a remote warning. If there are no alarm symptoms in the patient symptom data, the smart wearable device does not issue a remote warning;

[0209] When the gynecological oncology chemotherapy patient is a second follow-up type gynecological oncology chemotherapy patient, the smart wearable device directly issues a remote warning;

[0210] It should be noted here that:

[0211] In this application, the alarm symptoms are the dangerous clinical symptoms that occurred in historical gynecological oncology chemotherapy patients, and specifically need to be set according to the specific condition of the patient;

[0212] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the present invention to only the specific implementation manners. Obviously, according to the content of this specification, many modifications and changes can be made. This specification selects and specifically describes these embodiments in order to better explain the principle and practical application of the present invention, so that those skilled in the art in the relevant technical field can well understand and utilize the present invention. The present invention is only limited by the claims and their full scope and equivalents.

Claims

1. A portable remote follow-up method and system for gynecological tumor chemotherapy patients based on AI large model, characterized in that: include: Step S1: obtaining a portable index monitoring period, performing periodic heart rate index monitoring on gynecological tumor chemotherapy patients who are in the portable index monitoring period, and obtaining abnormal heart rate portable monitoring values ​​according to the monitoring results; Step S2: performing periodic blood oxygen index monitoring on gynecological tumor chemotherapy patients who are in the portable index monitoring period, and obtaining abnormal blood oxygen portable monitoring values ​​according to the monitoring results; Step S3: Gynecological tumor chemotherapy patients are divided into first follow-up type gynecological tumor chemotherapy patients and second follow-up type gynecological tumor chemotherapy patients according to abnormal values ​​of the heart rate portable monitoring and abnormal values ​​of the blood oxygen portable monitoring, and remote follow-up warnings are performed for each type.

2. According to claim 1, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S1 further includes the following specific steps: Step S11: Obtain the monitoring period of the portable indicator; Step S12: marking the heart rate monitoring time point X1 to the heart rate monitoring time point Xa within the portable indicator monitoring period; Step S13: respectively obtaining the heart rate values ​​corresponding to the heart rate monitoring time point X1 to the heart rate monitoring time point Xa of the gynecological tumor chemotherapy patient, and obtaining the heart rate values ​​X1 to Xa of the patient; Step S14: obtaining the normal heart rate interval corresponding to the gynecological tumor chemotherapy patient, and obtaining the median of the normal heart rate interval to obtain the patient's heart rate baseline value; Step S15: obtaining the periodic abnormal heart rate quantity ratio; Step S16: Obtain the patient's periodic heart rate deviation; Step S17: Calculate the average of the heart rate values ​​from X1 to Xa of the patient to obtain the average heart rate of the patient's cycle, calculate the difference between the average heart rate of the patient's cycle and the patient's heart rate reference value, and take the absolute value of the obtained difference to obtain the patient's cycle heart rate deviation; Step S18: Calculating the abnormal heart rate value of the portable heart rate monitoring by taking into account the average deviation of the abnormal heart rate of the period, the deviation of the patient's periodic heart rate and the number of abnormal heart rates of the period; Calculate abnormal values ​​of heart rate monitoring.

3. According to claim 2, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S15 further includes the following specific steps: Step S151: when the patient's Xi heart rate value is within the normal heart rate range, the Xi heart rate value is marked as a normal heart rate value; when the patient's Xi heart rate value is not within the normal heart rate range, the Xi heart rate value is marked as an abnormal heart rate value; Step S152: Count the abnormal heart rate values ​​from the heart rate value of patient X1 to the heart rate value of Xa to obtain the abnormal heart rate quantity value, calculate the ratio of the abnormal heart rate value to a, and obtain the periodic abnormal heart rate quantity ratio.

4. According to claim 2, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S16 further includes the following specific steps: Step S161: acquiring the left boundary of the normal heart rate interval to obtain a first interval boundary value, and acquiring the right boundary value of the normal heart rate interval to obtain a second interval boundary value; Step S162: if the heart rate value of patient Xj is greater than the boundary value of the second interval, the difference between the heart rate value of patient Xj and the boundary of the second interval is calculated, and the absolute value of the obtained difference is taken to obtain the abnormal heart rate deviation corresponding to the heart rate monitoring time point of Xj; Step S163: if the heart rate value of patient Xj is less than the first interval boundary value, the difference between the heart rate value of patient Xj and the first interval boundary is calculated, and the absolute value of the obtained difference is taken to obtain the abnormal heart rate deviation corresponding to the heart rate monitoring time point of Xj; Step S164: respectively obtaining the abnormal heart rate deviation corresponding to each abnormal heart rate value to obtain a plurality of abnormal heart rate deviations, and averaging the obtained plurality of abnormal heart rate deviations to obtain an average deviation of the periodic abnormal heart rate.

5. According to claim 1, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S2 further includes the following specific steps: Step S21: Marking the blood oxygen monitoring time point Y1 to the blood oxygen monitoring time point Yb within the portable indicator monitoring cycle; Step S22: Obtain the patient's blood oxygen values ​​corresponding to the Y1 blood oxygen monitoring time point to the Yb blood oxygen monitoring time point of the gynecological tumor chemotherapy patient, and obtain the patient's Y1 blood oxygen value to the Yb blood oxygen value; Step S23: obtaining the normal blood oxygen interval corresponding to the gynecological tumor chemotherapy patients through big data, and obtaining the median of the normal blood oxygen interval to obtain the patient's blood oxygen baseline value; Step S24: Obtaining the periodic abnormal blood oxygen quantity ratio; Step S25: Obtaining the average deviation of periodic abnormal blood oxygen; Step S26: Calculate the average of the patient's blood oxygen values ​​from Y1 to Yb to obtain the patient's periodic blood oxygen average value, calculate the difference between the patient's periodic blood oxygen average value and the patient's blood oxygen baseline value, and take the absolute value of the obtained difference to obtain the patient's periodic blood oxygen deviation; Step S27: Calculate the abnormal blood oxygen value of the portable blood oxygen monitoring system by using the average deviation of the abnormal blood oxygen value of the period, the deviation of the patient's periodic blood oxygen value and the ratio of the number of abnormal blood oxygen values ​​of the period; Calculate abnormal values ​​of blood oxygen monitoring.

6. According to claim 5, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S24 further includes the following specific steps: Step S241: if the patient's Ym blood oxygen value is within the normal blood oxygen range, the Ym blood oxygen value is marked as a normal blood oxygen value; if the patient's Ym blood oxygen value is not within the normal blood oxygen range, the Ym blood oxygen value is marked as an abnormal blood oxygen value; Step S242: Count the abnormal blood oxygen values ​​from the patient's blood oxygen value Y1 to the patient's blood oxygen value Yb to obtain the abnormal blood oxygen value, calculate the ratio of the abnormal blood oxygen value to b, and obtain the periodic abnormal blood oxygen value ratio.

7. According to claim 5, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S25 further includes the following specific steps: Step S251: acquiring the left boundary of the normal blood oxygen interval to obtain a first blood oxygen interval boundary value, and acquiring the right boundary value of the normal blood oxygen interval to obtain a second blood oxygen interval boundary value; Step S252: If the patient's Yn blood oxygen value is greater than the second blood oxygen interval boundary value, the difference between the patient's Yn blood oxygen value and the second blood oxygen interval boundary value is calculated, and the absolute value of the obtained difference is taken to obtain the blood oxygen abnormality deviation corresponding to the Yn blood oxygen monitoring time point; Step S253: If the patient's Yn blood oxygen value is less than the first blood oxygen interval boundary value, the difference between the patient's Yn blood oxygen value and the first blood oxygen interval boundary value is calculated, and the absolute value of the obtained difference is taken to obtain the blood oxygen abnormality deviation corresponding to the Yn blood oxygen monitoring time point; Step S254: respectively obtain the abnormal blood oxygen deviation corresponding to each abnormal blood oxygen value to obtain a plurality of abnormal blood oxygen deviations, and average the obtained plurality of abnormal blood oxygen deviations to obtain a periodic abnormal blood oxygen average deviation.

8. According to claim 1, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S3 further includes the following specific steps: Step S31: respectively obtaining abnormal values ​​of the heart rate portable monitoring system and abnormal values ​​of the blood oxygen portable monitoring system; Step S32: Calculating the abnormal value of the heart rate portable monitoring and the abnormal value of the blood oxygen portable monitoring to obtain the physiological index portable monitoring coefficient; The physiological index portable monitoring coefficient is calculated, and the specific formula is as follows: Slx=Xyy×a1+Xly Among them, Slx is the physiological index portable monitoring coefficient, Xyy is the abnormal value of blood oxygen portable monitoring, a1 is the set proportional coefficient, and Xly is the abnormal value of heart rate portable monitoring; Step S33: obtaining a physiological indicator monitoring coefficient interval; if the physiological indicator portable monitoring coefficient is within the physiological indicator monitoring coefficient interval, then the corresponding gynecological tumor chemotherapy patient is determined to be a first follow-up type gynecological tumor chemotherapy patient; if the physiological indicator portable monitoring coefficient is not within the physiological indicator monitoring coefficient interval, then the corresponding gynecological tumor chemotherapy patient is determined to be a second follow-up type gynecological tumor chemotherapy patient; Step S34: remote follow-up warning is performed on the first follow-up type gynecological tumor chemotherapy patients and the second follow-up type gynecological patients respectively.

9. According to claim 8, a method and system for remote follow-up of gynecological tumor chemotherapy patients based on AI large model, characterized in that: The step S34 further includes the following specific steps: Step S341: When the gynecological tumor chemotherapy patient is a gynecological tumor chemotherapy patient of the first follow-up type, the gynecological tumor chemotherapy patient can choose to conduct current symptom Q&A with the A1 model built into the smart wearable device. The A1 model extracts text from the current symptoms output by the gynecological tumor chemotherapy patient through voice to obtain patient symptom data, and compares the patient symptom data with the built-in alarm symptoms. If the patient symptom data contains alarm symptoms, the smart wearable device issues a remote warning. If the patient symptom data does not contain alarm symptoms, the smart wearable device does not issue a remote warning. Step S342: When the gynecological tumor chemotherapy patient is a gynecological tumor chemotherapy patient of the second follow-up type, the smart wearable device directly issues a remote warning.

10. A portable remote follow-up system for gynecological tumor chemotherapy patients based on AI large model, applicable to a portable remote follow-up method for gynecological tumor chemotherapy patients based on AI large model as described in any one of claims 1 to 9, characterized in that: The portable remote follow-up system for gynecological tumor chemotherapy patients includes: Heart rate indicator module: used to obtain the portable indicator monitoring cycle, perform periodic heart rate indicator monitoring on gynecological tumor chemotherapy patients who are in the portable indicator monitoring cycle, and obtain abnormal heart rate monitoring values ​​based on the monitoring results; Blood oxygen index module: used to perform periodic blood oxygen index monitoring on gynecological tumor chemotherapy patients who are in the portable index monitoring period, and obtain abnormal blood oxygen portable monitoring values ​​based on the monitoring results; Follow-up warning module: According to the abnormal values ​​of heart rate monitoring and blood oxygen monitoring, gynecological tumor chemotherapy patients are divided into first follow-up type gynecological tumor chemotherapy patients and second follow-up type gynecological tumor chemotherapy patients, and remote follow-up warnings are carried out for each type.

Images